To that end, our next studies determine the effects of imipramine in gemcitabine-mediated MVP release, and demonstrate that pretreatment of imipramine blocked not only gemcitabine, but also CPAF- and PMA-mediated MVP release from pancreatic cancer cells, indicating the role of aSMase in this effect. Here, SMPD1 is linked to pancreatic neoplasm.